(Q27693878)

April W. Armstrong

series ordinal

2

1 reference

language of work or name

English

0 references

publication date

March 2014

1 reference

1 March 2014

3 references

12 March 2019

13 March 2019

17 June 2019

4 references

12 March 2019

13 March 2019

17 June 2019

74

1 reference

issue

4

1 reference

page(s)

423-41

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

copyright license

start time

25 February 2014

1 reference

April 2022 Public Data File from Crossref

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Leflunomide: mode of action in the treatment of rheumatoid arthritis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Keynote review: phosphodiesterase-4 as a therapeutic target

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Burden of disease: psoriasis and psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Management of psoriatic arthritis from the view of the dermatologist

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Psoriatic arthritis: update on pathophysiology, assessment and management

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Harnessing dendritic cells in inflammatory skin diseases.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Psoriatic arthritis - update on pathophysiology, assessment, and management.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Gout: epitome of painful arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Genetic susceptibility factors for psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Spondyloarthritis is associated with poor function and physical health-related quality of life

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Investigation of association of the IL12B and IL23R genes with psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Treatment recommendations for psoriatic arthritis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Genetics of psoriasis and psoriatic arthritis: update and future direction.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Cyclic AMP: master regulator of innate immune cell function.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Psoriasis and psoriatic arthritis: separate or one and the same?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Predictors for radiological damage in psoriatic arthritis: results from a single centre

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

The psychosocial burden of psoriasis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

TNFalpha polymorphisms and risk of psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Psoriatic arthritis and psoriasis: need for a multidisciplinary approach

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Dactylitis in psoriatic arthritis: a marker for disease severity?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

29 September 2017

Psoriasis and arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Diagnosis and management of psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Mechanisms of action of cyclosporine.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Immunity at the surface: homeostatic mechanisms of the skin immune system.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Familial occurrence of psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Psoriasis causes as much disability as other major medical diseases

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Treatment of psoriatic arthritis with sulphasalazine: a one year open study.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Longitudinal study of clinical and radiological progression in psoriatic arthritis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Impact of psoriasis on patients' work and productivity: a retrospective, matched case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Work disability and health-related quality of life in males and females with psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Meta-analysis of NOD2/CARD15 polymorphisms with psoriasis and psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

IL-17 receptor and its functional significance in psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Diagnosis of fibromyalgia syndrome-a comparison of Association of the Medical Scientific Societies in Germany, survey, and American College of Rheumatology criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

The diagnostic value of the proposal for clinical gout diagnosis (CGD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire: a report from the GRAPPA 2009 annual meeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

The electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): a sensitive and specific tool to diagnose psoriatic arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Nailing down the genetic and immunological basis for psoriatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

The diagnosis of early psoriatic arthritis in an outpatient dermatological centre for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Psoriasis associated with rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

The Cytokine Network in Lesional and Lesion-Free Psoriatic Skin Is Characterized by a T-Helper Type 1 Cell-Mediated Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

PSORS2 Markers Are Not Associated with Psoriatic Arthritis in the Italian Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Psoriasis: an epidemiological evaluation of disease burden in 590 patients

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Analysis of 6 genetic loci for disease susceptibility in psoriatic arthritis

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Sulfasalazine improves psoriasis. A double-blind analysis.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958815

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

27 November 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0191-Y

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

21 January 2018

1 reference

12 December 2020

Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

1 reference

12 December 2020

HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype

1 reference

12 December 2020

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

1 reference

12 December 2020

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

12 December 2020

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis

1 reference

12 December 2020

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

1 reference

12 December 2020

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study

1 reference

12 December 2020

High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice

1 reference

12 December 2020

Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis

1 reference

12 December 2020

1 reference

12 December 2020

Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study

1 reference

12 December 2020

Etanercept as monotherapy in patients with psoriasis

1 reference

12 December 2020

A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience

1 reference

12 December 2020

Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction

1 reference

12 December 2020

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

12 December 2020

Normal individuals with positive tests for rheumatoid factor

1 reference

12 December 2020

1 reference

12 December 2020

Generalized pustular psoriasis precipitated by phenylbutazone and oxyphenbutazone

1 reference

12 December 2020

Exacerbation of psoriasis with meclofenamate

1 reference

12 December 2020

Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis

1 reference

12 December 2020

Exacerbation of psoriasis by ibuprofen

1 reference

12 December 2020

Exacerbation of psoriasis by indomethacin

1 reference

12 December 2020

Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study

1 reference

12 December 2020

Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: Results of a multicenter study

1 reference

12 December 2020

Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study

1 reference

12 December 2020

Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study

1 reference

12 December 2020

Cyclosporine as maintenance therapy in patients with severe psoriasis

1 reference

12 December 2020

Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study

1 reference

12 December 2020

Antibodies to cyclic citrullinated peptides in psoriatic arthritis

1 reference

12 December 2020

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

12 December 2020

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

12 December 2020

Classification criteria for psoriatic arthritis: development of new criteria from a large international study

1 reference

12 December 2020

Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices

1 reference

12 December 2020

LABORATORY FINDINGS IN PSORIATIC ARTHRITIS

1 reference

12 December 2020

Combination biologic treatment of refractory psoriasis and psoriatic arthritis

1 reference

12 December 2020

Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort

1 reference

12 December 2020

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

1 reference

12 December 2020

Identification of interleukin-7 as a candidate disease mediator in spondylarthritis

1 reference

12 December 2020

Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy

1 reference

12 December 2020

Genetic Variants of the IL-23R Pathway: Association with Psoriatic Arthritis and Psoriasis Vulgaris, but No Specific Risk Factor for Arthritis

1 reference

12 December 2020

Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis

1 reference

12 December 2020

Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire

1 reference

12 December 2020

Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis

1 reference

12 December 2020

The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients

1 reference

12 December 2020

Inflammatory musculoskeletal disease: identification and assessment

1 reference

12 December 2020

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

1 reference

12 December 2020

10.1007/S40265-014-0191-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

1052835422

0 references

1 reference

1 reference

PubMed publication ID

24566842

1 reference